Lately another company has come onto the US marketplace to compete with the reknowned brand Botox, an Allergan product. Botox has reigned supreme in the medical cosmetics market in the US, with few real competitors. Up to now the primary competitor to Botox in the States has been Dysport, though many medical practitioners have avoided employing this version of Botulinum Toxin for in-office aesthetics due to some proof suggesting that the drug tends to exhibit more local spread.
Merz is the manufacturer of Xeomin, a botulinum toxin medication. Xeomin has been popular in Europe and enjoyed by physicians and consumers alike. Last year in July, Merz announced that the FDA had authorised Xeomin for aesthetic procedures in the States and that the injectable would be available for sale in mid-2012. This development is a bonus for aesthetics consumers!
While in America Xeomin is a comparatively unknown brand it’s got many benefits over the more famous injectable Botox. Botox must be either stored in a fridge or frozen before reconstitution and is very sensitive to temperature extremes as well as to agitation. For example, when reconstituting Botox, doctors must be extremely careful to insert the solution slowly, since rapid insertion could render the product inactive.
Xeomin, on the other hand, is a far more durable substance. A substantial benefit over Botox is that Xeomin can be kept at 70 degrees and so does not need special storage measures. Additionally Xeomin is a lot less sensitive to physical irritation. This means that on the part of the aesthetic practice less vials will be harmed due to poor handling or storage.
Versus the other Botox substitute, Dysport, Xeomin is way more like Botox in terms of its pharmacological profile. Xeomin injections generally remain localized, meaning potentially less side effects associated with local spread. Additionally a major advantage is that the units used are similar to the units utilized by Botox, in constrast to Dysport where the units aren’t similar and can be confusing for doctors.
Also, if the American market follows the European Union, the introduction of Xeomin will lead to competition which will mean cheaper prices for consumers. At the moment the cost of Botox in the USA has a tendency to be around $9-12 per unit, while the price in Great Britain tends to be significantly lower at approximately $7-8 per unit.
Hence the impending penetration of Xeomin into the United States market place will be a boon for both clients as well as doctors.
Botox Course runs the #1 injection course for doctors and dentists to instruct them how to inject Botox and start succesful aesthetic day spas. In addition to the Botox Injection Course, physicians can learn hyaluronic acid injection techniques and chemical peeling techniques.
{ 0 коментара… прибавете свой сега }